(MedPage Today) — In the recently reported NEPTUNUS-1 and -2 trials, presented at this year’s American College of Rheumatology (ACR) annual meeting, investigators found that the anti-B-cell activating factor receptor (BAFF-R) antibody ianalumab…
Source link : https://www.medpagetoday.com/meetingcoverage/acrexpertroundtable/118909
Author :
Publish date : 2025-12-09 16:45:00
Copyright for syndicated content belongs to the linked Source.
